BELLUS Health, the streamlined and focused drug development company concentrating on rare diseases, this week reported full year December 2014 results with a loss of C$1.9m, an improvement on our expectation of C$3m and a better than expected C$12.3m year end cash balance. On its lead program KIACTATM for AA Amyloidosis, the company revealed that the final enrolment figure for the Phase III Confirmatory Study reached 261 patients vs a target of 230, which in our opinion provides additional co ....